Skip to main content

Table 2 Association of ROR1 with: TTF-1 expression; EGFR, KRAS mutations by median and cut-off

From: Functional and clinical significance of ROR1 in lung adenocarcinoma

Overall population ROR1 expression
≤ median >median p value cut-off ≤1 cut-off > 1 p value
EGFR wt 25 26 0.7027 37 14 0.5569
mut 2 3 3 2
KRAS wt 14 16 0.8051 20 10 0.4011
mut 13 13 20 6
TTF-1 neg 6 5 0.6422 8 3 0.9161
pos 21 24 32 13
Localized disease ROR1 expression
≤ median >median p value cut-off ≤1 cut-off > 1 p value
EGFR wt 24 23 0.6413 34 13 0.5663
mut 2 3 3 2
KRAS wt 13 14 0.7834 17 10 0.1797
mut 13 12 20 5
TTF-1 neg 6 5 0.7367 8 3 0.8978
pos 20 21 29 12
Advanced disease ROR1 expression
≤ median >median p value cut-off ≤1 cut-off > 1 p value
EGFR wt 1 3 0 3 1 0
mut 0 0 0 0
KRAS wt 1 2 0.5637 3 0 0.0833
mut 0 1 0 1
TTF-1 neg 0 0 0 0 0 0
pos 1 3 3 1
  1. Statistical evaluation of ROR1 expression distribution, estimated by the median and the cut-off (equal to 1), among the analyzed molecular markers: EGFR, KRAS mutations; TTF-1 expression. The p values results and the severity of the disease are reported in bold
\